Aurobindo Pharma Q3 FY23 net profit down 18.7% at Rs 491 Crores
Revenue from operations during the quarter was up by 6.7 per cent to Rs 6,407.10 crore against Rs 6,002.2 in the same period last fiscal.
Revenue from operations during the quarter was up by 6.7 per cent to Rs 6,407.10 crore against Rs 6,002.2 in the same period last fiscal.
SEEDS is a mnemonic for Shun Tobacco, Eat Correctly, Exercise Regularly, Dump obesity and excess alcohol, and Stay vigilant about your family history aims at making more and more people aware about the tenets of cancer prevention
For discovery or for standardization, Ayurveda colleges/institutes need to collaborate closely with Phytochemists, Pharmacologists, and Toxicologists from premier institutions
CHMP recommendation is based on Phase III data, which demonstrated that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel significantly reduced the risk of death by 32.5%
Approval marks fifth indication for KEYTRUDA-based regimens in NSCLC and 34th indication for KEYTRUDA in the US
The Durezol brand and generic had US sales of approximately US $40 million MAT for the most recent twelve months ending in Nov 2022 according to IQVIA
The company is adding new capabilities of Combi-line for Microsphere, additional Bag line and lyos for the Penem block in Pashamylaram facility in Hyderabad and will be earmarking capital for further building on its Biosimilar CDMO facility
The top 15 Indian pharma players have continued to experience anaemic growth in the US market over the five years ended FY22
This DSIR recognition for company's in-house R&D Unit make it eligible for receiving funds for R&D purpose from various government departments and agencies
Launch of Apollo Genomics Institutes would provide genetic counselling, tests, treatment and care for genetic disorders
Subscribe To Our Newsletter & Stay Updated